| Abstrakt: |
Probiotics, including Lactic Acid Bacteria (LAB), have gained considerable attention due to their potential health benefits for humans and animal livestock. This research aimed to isolate probiotic bacteria of human origin and explore their therapeutic potential against Campylobacterstrains, which are recognized as the leading bacterial cause of human gastroenteritis worldwide. A collection of 230 LAB isolates from human stools were screened for the ability of cell free supernatants to inhibit the growth of three strains of C. jejuniand a C. coli. Co-culture and agar-well diffusion assays identified seven isolates with inhibitory activity against Campylobacterssp., which were characterized as probiotic strains by their tolerance to pH 2 and bile salts, and then identified as Enterococcusspp. using 16S rRNA gene sequencing:: E. faecalisNM231, E. faeciumNM234, E. faeciumNM233, E. faeciumNM113, E. duransNM232, E. faecalisNM235, and E. faeciumNM236. In vivo evaluation was undertaken by the oral administration of selected probiotics to groups of mice prior to challenge with C. jejuni. Histopathological examinations showed challenge groups receiving either mixed probiotics or E. faeciumNM234 were protected against C. jejuni-induced jejunal, colonic, ovarian and uterine tissue damage. Immunohistochemical detection of the challenged mice revealed the presence of C. jejuniantigen in jejunal, colonic, ovarian and uterine sections but was absent in mice receiving either mixed probiotics or E. faeciumNM234. This study introduces E. faeciumNM234 as a promising probiotic against Campylobacter. |
Full Text from ScienceDirect